Q-omics provides the consensus-scored SLC44A5 profile across patient tissues and cancer cell-line models. SLC44A5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC44A5 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, SLC44A5 RNA expression shows 16,711 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where SLC44A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC44A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC44A5 survival associations across molecular data types. SLC44A5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC44A5 RNA expression–survival associations across cancer types. High SLC44A5 expression shows unfavorable associations in KIRP, LIHC, UVM and KIRC, but favorable associations in UCS and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC44A5 RNA expression.
This table summarizes SLC44A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC44A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC44A5 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LUSC, LUAD and LIHC. The HNSC box plot shows higher SLC44A5 RNA expression in tumor versus normal tissue (log2 FC = +1.499, t-test p < 0.001).
This table shows molecular features associated with SLC44A5 in patient tissues and cancer cell lines. In patient samples, SLC44A5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC44A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
